Eltrombopag Added to Immunosuppression in Severe Aplastic AnemiaRégis Peffault de Latour, Antonio M. Risitano, Fiorenza Barraco et al.|New England Journal of Medicine|2022Cited by 309
Eltrombopag Added to Standard Immunosuppressive Treatment Improves Long-Term Outcomes As Front-Line Therapy for Severe Aplastic Anemia: Final 2-Year Analysis of EBMT-Saawp Race StudyAntonio M. Risitano, Régis Peffault de Latour, S. Iacobelli et al.|Blood|2024Cited by 1
Allogeneic hematopoietic cell transplantation in dyskeratosis congenita: Short and long- term outcome of 183 consecutive patients transplanted at EBMT centersFabiana Cacace, Antonio M. Risitano, Filomena Pierri et al.|Blood|2025Cited by 1
<scp>Eltrombopag</scp> Added to Standard Immunosuppressive Treatment as Front‐Line Therapy for Severe Aplastic Anemia: Long‐Term Outcomes of the Phase‐3 Randomized Superiority <scp>EBMT</scp> ‐ <scp>SAAWP RACE</scp> StudyAntonio M. Risitano, Ghulam J. Mufti, Simona Iacobelli et al.|American Journal of Hematology|2026Cited by 0